To include your compound in the COVID-19 Resource Center, submit it here.

August ramblings

Thoughts as the dog days of summer begin to wind down:

Price oversight

While the specter of mandatory drug price controls seems to be evaporating from President Clinton's health plan, a government watchdog on pricing decisions looks to be in the cards. The optimistic scenario is that the watchdog will be armed only with a jawbone, which it would wave around if it found self-restraint lacking among the drug companies. Of course, anything can happen once Congress gets hold

Read the full 789 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers